Evogene (EVGN) Revenue (2012 - 2026)
Evogene (EVGN) posted Revenue of $334000.0 for Q1 2026, up 6.37% sequentially from $314000.0 in Q4 2025, and down 85.74% YoY from $2.3 million in Q1 2025.
Evogene (EVGN) Revenue (2012 - 2026) Analysis & Trends
Evogene has reported Revenue for 15 years, with the latest figure at $334000.0 in Q1 2026.
- Quarterly Revenue fell 85.74% year-over-year to $334000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 70.41% YoY) and the FY2025 annual result came in at $3.9 million, down 30.91% from the prior year.
- Revenue improved to $334000.0 in Q1 2026 per EVGN's latest filing, from $314000.0 in the prior quarter.
- Over five years, Revenue peaked at $4.2 million in Q1 2024 and troughed at $237000.0 in Q1 2022.
- A 5-year average of $1.2 million and a median of $641000.0 in 2023 frame the typical range for Revenue.
- The sharpest annual moves came in 2023 and 2026: Revenue soared 708.37% in 2023, then sank 85.74% in 2026.
- Over 5 years, Revenue stood at $660000.0 in 2022, then decreased by 12.42% to $578000.0 in 2023, then soared by 166.96% to $1.5 million in 2024, then tumbled by 79.65% to $314000.0 in 2025, then increased by 6.37% to $334000.0 in 2026.
- According to Business Quant data, Revenue over the past three periods registered $334000.0, $314000.0, and $312000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 674.14 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 334,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 334,000.00 |
| Dec 31, 2025 | 314,000.00 |
| Sep 30, 2025 | 312,000.00 |
| Jun 30, 2025 | 884,000.00 |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 605,000.00 |
| Mar 31, 2024 | 4.19 Mn |
| Dec 31, 2023 | 578,000.00 |
| Sep 30, 2023 | 3.77 Mn |
| Jun 30, 2023 | 654,000.00 |
| Mar 31, 2023 | 641,000.00 |
| Dec 31, 2022 | 660,000.00 |
| Sep 30, 2022 | 466,000.00 |
| Jun 30, 2022 | 312,000.00 |
| Mar 31, 2022 | 237,000.00 |
| Dec 31, 2021 | 311,000.00 |
| Sep 30, 2021 | 151,000.00 |
| Jun 30, 2021 | 135,000.00 |